Loading patent…
AssigneeNovo Nordisk A/S
InventorsSoeren Oestergaard, Kilian Waldemar Conde Frieboes, Birgit Wieczorek, Jens Kaalby Thomsen, Birgitte Schjellerup Wulff, Carsten Jessen
Estimating the term…
The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.
A PYY compound comprising tryptophan at the position corresponding to position 30 of hPYY(1-36) (SEQ ID NO:1), a maximum of 8 amino acid modifications as compared to hPYY(3-36), wherein the PYY compound comprises N(alpha)-methyl-L-arginine at a position corresponding to position 35 of hPYY(1-36) (SEQ ID NO:1), and wherein the positions corresponding to positions 1-2 or 1-3 of hPYY(1-36) (SEQ ID NO:1) are absent, or a pharmaceutically acceptable salt thereof.
A PYY compound selected from the following:
A pharmaceutical composition comprising liraglutide or semaglutide, and the PYY compound of SEQ ID NO:18.
Dependencies are inferred from the claim text.